Press Release Details
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on
– Pooled
– Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: Three-Year Data from the PALISADE Study and the Open-Label Extension Will Be Presented in Moderated Poster Session –
AHA 2026 Oral Presentations
Date & Time:
Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies
Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall
Title: First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia (ARO-DIMER-PA)
Presenter:
Date & Time:
Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies
Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall
Title: Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction with Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of
Presenter:
Moderated Poster Sessions
Date & Time:
Session Title: PL.MDP.01: Transforming Lipid Care Across the Lifespan
Location: Moderated Digital Poster 21‚
Topic: Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: 3-Year Data from the PALISADE Study and the Open-Label Extension
Presenter:
Date & Time:
Session Title: PL.MDP.01: Innovations in Lipid Science: Emerging Therapies and Population Impact
Location: Moderated Digital Poster 22‚
Topic: Impact of GLP-1 Receptor Agonist Use on Triglyceride Reduction with Plozasiran, PL.MDP.05: Innovations in Lipid Science: Emerging Therapies and Population Impact
Presenter:
About ARO-DIMER-PA
ARO-DIMER-PA is an investigational dual-functional RNAi molecule designed to silence expression of both PCSK9 and APOC3 genes in hepatocytes. Prior clinical experience with other investigational and approved agents suggests that PCSK9 and APOC3 inhibition may lead to robust reductions in LDL-C, triglycerides (TGs), triglyceride-rich lipoprotein remnants, and total atherogenic lipoproteins.
ARO-DIMER-PA is the first clinical candidate designed to selectively silence the expression of two genes with a single RNAi molecule. ARO-DIMER-PA-1001 (NCT07223658) is a Phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects on LDL-C and triglycerides of single and multiple doses of ARO-DIMER-PA in adults with mixed hyperlipidemia.
About Mixed Hyperlipidemia
Mixed hyperlipidemia is a highly prevalent disorder characterized by elevated levels of both low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) and is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of mortality worldwide and associated with substantial morbidity and healthcare costs. Despite the efficacy of LDL-C-lowering therapies in reducing ASCVD risk, there remains substantial residual risk in patients with mixed hyperlipidemia.
About
About Plozasiran in the Treatment of Severe Hypertriglyceridemia
Plozasiran, the active ingredient in REDEMPLO, was granted Breakthrough Therapy designation in
About Severe Hypertriglyceridemia
Severe hypertriglyceridemia (sHTG) is characterized by TG levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride-rich lipoproteins, particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of ASCVD. Limited treatment options exist to sustainably reduce TGs below guideline-directed risk thresholds.
About REDEMPLO® (plozasiran)
REDEMPLO (plozasiran) is currently approved by the
REDEMPLO is designed to suppress the production of apolipoprotein C-III (APOC3), a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting APOC3 with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is self-administered via subcutaneous injection once every three months.
REDEMPLO has been granted Orphan Medicinal Product Designation by the EMA for the treatment of patients with
Sanofi acquired the rights to develop and commercialize REDEMPLO in
For more information about REDEMPLO, visit Our Medicines.
About Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome (FCS) is a severe and rare genetic disease often caused by various monogenic mutations.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The Company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidates, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO® (plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; our beliefs and expectations regarding the potential safety, efficacy, and therapeutic benefit of ARO-DIMER-PA and plozasiran in sHTG; the timing of any regulatory submissions for plozasiran in sHTG; and our beliefs and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties including but not limited to the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102145649/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
+1 626-304-3400
ir@arrowheadpharma.com
Paul Graves
+1 626-304-3400
media@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
+1 212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
+1 724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.